Effects of Tirzepatide (TZP), a Novel Dual GIP and GLP-1 Receptor Agonist, on Biomarkers of Nonalcoholic Steatohepatitis (NASH) in Patients with T2D

被引：4
|
作者：
Hartman, Mark L.
Sanyal, Arun
Loomba, Rohit
Wilson, Jonathan M.
Bray, Ross
Nikooienejad, Amir
Duffin, Kevin L.
Robins, Deborah A.
Haupt, Axel
机构：
来源：
DIABETES | 2019年 / 68卷
关键词：
D O I：
10.2337/db19-134-OR
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
134-OR
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes
    Hartman, Mark L.
    Sanyal, Arun J.
    Loomba, Rohit
    Wilson, Jonathan M.
    Nikooienejad, Amir
    Bray, Ross
    Karanikas, Chrisanthi A.
    Duffin, Kevin L.
    Robins, Deborah A.
    Haupt, Axel
    [J]. DIABETES CARE, 2020, 43 (06) : 1352 - 1355
  • [2] Effects of tirzepatide (TZP), a novel dual GIP and GLP-1 receptor agonist, on biomarkers of non-alcoholic steatohepatitis (NASH) in patients with type 2 diabetes
    Haupt, A.
    Sanyal, A.
    Loomba, R.
    Wilson, J.
    Bray, R.
    Nikooienejad, A.
    Duffin, K.
    Robins, D.
    Hartman, M.
    [J]. DIABETOLOGIA, 2019, 62 : S91 - S91
  • [3] EFFECTS OF TIRZEPATIDE, A NOVEL DUAL GIP AND GLP-1 RECEPTOR AGONIST, ON BIOMARKERS OF NON-ALCOHOLIC STEATOHEPATITIS (NASH) IN PROBABLE NASH SUBGROUPS OF PATIENTS WITH TYPE 2 DIABETES (T2D)
    Hartman, Mark
    Loomba, Rohit
    Sanyal, Arun J.
    Wilson, Jonathan M.
    Nikooienejad, Amir
    Bray, Ross
    Duffin, Kevin L.
    Robins, Deborah A.
    Haupt, Axel
    [J]. HEPATOLOGY, 2019, 70 : 1270A - 1271A
  • [4] Tirzepatide: A Novel Dual GIP and GLP-1 Receptor Agonist
    Wong, Elaine
    [J]. JNP- THE JOURNAL FOR NURSE PRACTITIONERS, 2023, 19 (01):
  • [5] THE DUAL GIP AND GLP-1 RECEPTOR AGONIST TIRZEPATIDE IMPROVES BIOMARKERS ASSOCIATED WITH CARDIOVASCULAR RISK IN PATIENTS WITH TYPE 2 DIABETES (T2D)
    Wilson, J.
    Nikooienejad, A.
    Lin, Y.
    Robins, D.
    Roell, W.
    Riesmeyer, J.
    Haupt, A.
    Duffin, K.
    Ruotolo, G.
    [J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2021, 23 : A164 - A165
  • [6] Effects of tirzepatide, a novel dual GIP and GLP-1 receptor agonist, on lipid profiling in patients with type 2 diabetes
    Ruotolo, G.
    Roth, K. D.
    Milligan, P. L.
    Lin, Y.
    Wilson, J. M.
    Pirro, V
    Duffin, K. L.
    Haupt, A.
    [J]. EUROPEAN HEART JOURNAL, 2020, 41 : 3056 - 3056
  • [7] Effects of tirzepatide, a novel dual GIP and GLP-1 receptor agonist, on metabolic profile in patients with type 2 diabetes
    Pirro, V.
    Willency, J. A.
    Wilson, J. M.
    Roth, K. D.
    Lin, Y.
    Collins, K. A. L.
    Ruotolo, G.
    Haupt, A.
    Newgard, C. B.
    Duffin, K. L.
    [J]. DIABETOLOGIA, 2020, 63 (SUPPL 1) : S73 - S73
  • [8] Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
    Willard, Francis S.
    Douros, Jonathan D.
    Gabe, Maria
    Showalter, Aaron D.
    Wainscott, David B.
    Suter, Todd M.
    Capozzi, Megan E.
    van der Velden, Wijnand J. C.
    Stutsman, Cynthia
    Cardona, Guemalli R.
    Urva, Shweta
    Emmerson, Paul J.
    Holst, Jens J.
    D'Alessio, David A.
    Coghlan, Matthew P.
    Rosenkilde, Mette M.
    Campbell, Jonathan E.
    Sloop, Kyle W.
    [J]. JCI INSIGHT, 2020, 5 (17)
  • [9] Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide
    Urva, Shweta
    Quinlan, Tonya
    Landry, John
    Martin, Jennifer
    Loghin, Corina
    [J]. CLINICAL PHARMACOKINETICS, 2021, 60 (08) : 1049 - 1059
  • [10] Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide
    Urva, Shweta
    Quinlan, Tonya
    Landry, John
    Ma, Xiaosu
    Martin, Jennifer A.
    Benson, Charles T.
    [J]. CLINICAL PHARMACOKINETICS, 2022, 61 (07) : 1057 - 1067
12345